Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $3.93M | $3.53M | $2.52M | $2.23M | $5.21M | $5.07M |
| Revenue growth | — | — | — | — | -10.2% | -28.5% | -11.6% | 133.6% | -2.8% |
| Operating income | — | -$959K | -$3.33M | -$1.61M | -$19.9M | -$24.2M | -$10.7M | -$6.73M | -$10.2M |
| Operating margin | — | — | — | -41.0% | -562.7% | -959.9% | -480.5% | -129.2% | -202.1% |
| Net income | — | $2.12M | $3.24M | -$161K | -$29.1M | -$24.2M | -$10.6M | -$7.99M | -$10.2M |
| Net margin | — | — | — | -4.1% | -825.4% | -959.3% | -476.4% | -153.3% | -200.8% |
| EPS (diluted) | — | -$0.22 | -$0.47 | $0.00 | -$1.48 | -$139.42 | -$70.40 | -$11.45 | -$3.98 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$1.24M | -$1.42M | -$1.25M | -$8.24M | -$17.9M | -$10.8M | -$7.50M | -$7.81M |
| Capital expenditures | — | — | — | — | — | — | — | — | $124K |
| Free cash flow | — | — | — | — | — | — | — | — | -$7.93M |
| Share buybacks | — | — | $11.6M | — | — | — | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | $194K | $12.3M | $3.15M | $1.12M | $3.50M | $4.31M |
| Total assets | $202M | $205M | $197M | $352K | $16.4M | $5.89M | $2.71M | $5.60M | $7.45M |
| Total liabilities | $7.16M | $7.44M | $10.3M | $7.01M | $24.6M | $9.91M | $3.36M | $2.22M | $4.57M |
| Shareholders' equity | $5.00M | $5.00M | $5.00M | -$6.44M | -$7.88M | -$3.71M | -$323K | $3.71M | $3.21M |
| Retained earnings | -$31.2K | $2.09M | $2.46M | -$56.0M | -$85.8M | -$111M | -$122M | -$130M | -$140M |
| Shares (wtd avg diluted) | 6.73M | 6.04M | 6.38M | 16.5M | 20.2M | 180K | 151K | 698K | 2.56M |
Every figure is extracted from Ensysce Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.